{
  "pmcid": "4828933",
  "sha256": "2ca7c1cb2293c383cf53f5a95bcfc136a1a6ea00e0e58f53718bce158c478177",
  "timestamp_utc": "2025-11-09T22:44:02.497476+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.51592950265572,
    "reading_ease": 4.25710043457272,
    "word_count": 218
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Intraoperative Molecular Imaging with a Targeted Contrast Agent for Lung Adenocarcinomas"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this randomised controlled trial, 50 patients with biopsy-proven lung adenocarcinoma were enrolled at a single surgical center."
      },
      "Participants": {
        "score": 2,
        "evidence": "50 patients with biopsy-proven lung adenocarcinoma were enrolled at a single surgical center."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were systemically administered 0.1 mg/kg of a fluorescent folate receptor alpha (FRÎ±)-targeted molecular contrast agent intravenously before surgery."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates a targeted molecular contrast agent for identifying lung adenocarcinomas via real-time optical imaging during surgery."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was the identification of fluorescent tumors, measured intraoperatively."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "In this randomised controlled trial, 50 patients with biopsy-proven lung adenocarcinoma were enrolled at a single surgical center."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of the 50 patients, 46 (92%) had fluorescent tumors."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Of the 50 patients, 46 (92%) had fluorescent tumors."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}